BioNTech Rises on Prelim Data from Cancer Treatment BNT316

BioNTech rose premarket on preliminary data from its phase 1/2 trial of cancer treatment BNT316/ONC-392, saying it demonstrated “encouraging signs of clinical anti-tumor activity.”

• Jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC)
• Initiation of a pivotal Phase 3 trial with BNT316/ONC-392 as monotherapy in immunotherapy-resistant NSCLC patients is planned in 3Q following FDA’s Fast Track designation in 2022
• Shares rose as much as 3.2% premarket

To view the source of this information, click here

To contact the reporter on this story:
Zachary Fleming in ...